In the present study, the association of this ERICH3 nsSNP with antidepressant response was also replicated in MDD patients enrolled in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study [31, 32], in which patients were treated with either an SSRI or a serotonin–norepinephrine reuptake inhibitor (SNRI). Here, ERICH3 is linked to depressive symptom measurement.